Table 4.
Precompetitive consortiums, scientific societies, and nonprofit organizations related to digital health
| Group/initiative | Description |
|---|---|
| Digital Medicine Society (DiMe) | Professional society for the digital medicine community, aimed at driving scientific progress and broad acceptance of digital medicine to enhance public health |
| TransCelerate BioPharma Patient Technology Initiative | TransCelerate BioPharma Inc. is a nonprofit organization with a mission to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective, and high‐quality delivery of new medicines. The Patient Technology Initiative strives to enable and accelerate patient‐facing technology in support of an improved patient experience and richer data collection in clinical trials. |
| Patient Centric Sampling Interest Group | Collaborative group across organizations in non‐competitive mutual areas of interest related to patient‐centric sampling |
| IQ Consortium Patient‐Centric Sampling Working Group |
The International Consortium for Innovation and Quality in Pharmaceutical Development is a technically‐focused organization of pharmaceutical and biotechnology companies with a mission of advancing science and technology to augment the capability of member companies to develop transformational solutions that benefit patients, regulators, and the broader research and development community. The goal of the patient centric sampling working group is to encourage the implementation of patient centric sampling within the industry to provide richer data sets and gain wider acceptance with regulators |
| Open Wearables Initiative (OWEAR) | Collaboration designed to promote the effective use of high‐quality, sensor‐generated measures of health in clinical research through the open sharing of algorithms and data sets |
| Adherence Measurement Institute | Nonprofit organization that is passionate about the need of more precise patient drug dosing data |
| Critical Path for Parkinson’s (CPP) Digital Drug Development Tools (3DT) Initiative | Precompetitive collaboration amongst a subset of CPP member organizations with the goal of optimizing the efficiency of paths for developing digital tools for Parkinson's disease drug development |
| Innovative Medicines Initiative (IMI) Projects | IMI is a European initiative public‐private partnership in the field of pharmaceutical research. There are several IMI projects related to digital health with specific areas of focus, including projects related to developing new ways of remotely monitoring disease and relapse in Alzheimer’s disease (RADAR‐AD) and in central nervous system disorders (RADAR‐CNS), exploring the potential of digital technologies for use in decentralized trials (Trials@Home), and aimed at connecting digital mobility assessments to clinical outcomes for regulatory and clinical endorsement (Mobilise‐D) |
| Clinical Trials Transformation Initiative (CTTI) | Comprises organizations from across the clinical trial enterprise, with a mission of developing and driving adoption of practices that will increase the quality and efficiency of clinical trials. CTTI develops recommendations and resources related to digital health technologies and trials |